GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.350
+0.020 (0.86%)
At close: Apr 4, 2025, 4:00 PM
2.300
-0.050 (-2.13%)
After-hours: Apr 4, 2025, 4:05 PM EDT

GT Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-13.16-7.6-20.88-58.01-28.3
Upgrade
Other Amortization
----0.32
Upgrade
Asset Writedown & Restructuring Costs
----0.06
Upgrade
Loss (Gain) From Sale of Investments
--0.050.030.03-
Upgrade
Stock-Based Compensation
0.232.27.6533.930.27
Upgrade
Other Operating Activities
-0.75-5.23-0.020.5117.98
Upgrade
Change in Accounts Payable
0.941.96-2.037.08-0.84
Upgrade
Change in Other Net Operating Assets
-0.16-0.140.040.863.24
Upgrade
Operating Cash Flow
-12.9-8.85-15.22-15.61-7.26
Upgrade
Investment in Securities
12.89-2.0112.15-23.04-
Upgrade
Investing Cash Flow
12.89-2.0112.15-23.04-
Upgrade
Short-Term Debt Issued
---1.2112.53
Upgrade
Total Debt Issued
---1.2112.53
Upgrade
Net Debt Issued (Repaid)
---1.2112.53
Upgrade
Issuance of Common Stock
2.986.27-41.11-
Upgrade
Repurchase of Common Stock
---0.22--
Upgrade
Financing Cash Flow
2.986.27-0.2242.3212.53
Upgrade
Net Cash Flow
2.97-4.59-3.33.675.27
Upgrade
Free Cash Flow
-12.9-8.85-15.22-15.61-7.26
Upgrade
Free Cash Flow Per Share
-6.80-6.57-14.32-16.63-49.68
Upgrade
Cash Interest Paid
-0.21---
Upgrade
Levered Free Cash Flow
-9.62-4.68-10.91-0.82-3.42
Upgrade
Unlevered Free Cash Flow
-9.62-4.55-10.9-0.38-1.66
Upgrade
Change in Net Working Capital
0.87-1.725.26-1.64-2.29
Upgrade
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q